Futurism on MSN1h
Evidence Is Growing That Ozempic Can Cause Blindness
As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more and more cases linking them ...
Neurology Advisor3d
Four in 10 Patients Receiving Chemo Develop Chronic Painful Neuropathy
The pooled prevalence of chronic painful neuropathy is 41.22% among individuals with chemotherapy-induced peripheral neuropathy (CIPN).
Scientific American13d
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Daily Excelsior1d
59-year-old GBS patient dies in Pune, death toll rises to eight
A 59-year-old man suffering from Guillain-Barre Syndrome (GBS) has died in a hospital here, taking the death toll due to the ...
GlobalData on MSN14d
FDA approves Vertex’s acute pain treatment Journavx
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Nature21d
Vincristine-Induced Peripheral Neuropathy in Pediatric Acute Lymphoblastic Leukemia
Vincristine is a commonly used chemotherapy drug in the treatment of pediatric acute lymphoblastic leukemia ... as vincristine-induced peripheral neuropathy (VIPN), which can significantly ...
Managed Healthcare Executive13d
FDA Approves Journavx, New Nonopioid Med, for Acute Pain
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...
Seeking Alpha11d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Data by YCharts Leading into and following FDA approval for acute pain, its stock has recovered some. Vertex is also studying Journavx in painful diabetic peripheral neuropathy [DPN]. The ...